Sentence examples for decrease in recurrence and from inspiring English sources
A second cohort comprising 9015 patients compared the switch strategy with standard tamoxifen treatment and showed a significant absolute decrease in recurrence and in breast cancer mortality of 3.1%and0.7%7%, respectively.
The meta-analysis of the adjuvant trials [130] analysed a cohort of 9856 patients where AI upfront therapy was compared with standard tamoxifen treatment, showing a significant 2.9% absolute decrease in recurrence and a non-significant absolute 1.1% decrease in breast cancer mortality.
A potentially important study is the Nurses Health Studyy, which reported an association between aspirin use and a decrease in distant recurrence and improved survival in women with breast cancer who had survived a minimum of one year following a cancer diagnosis [ 41].
In patients with high AIB1 expression (>75%), there was a significant decrease in recurrence rate (HR 0.40, 95% CI 0.26 0.61, P < 0.001) and breast cancer mortality rate (HR 0.38, 95% CI 0.21 0.69, P = 0.0015) with tamoxifen treatment.
At 5 years, AI therapy was associated with an absolute 2.9% (standard error (SE) = 0.7%) decrease in recurrence (9.6% for AI vs. 12.6% for tamoxifen; 2 P < 0.00001) and a nonsignificant absolute 1.1% (SE = 0.5%) decrease in breast cancer mortality (4.8% for AI vs. 5.9% for tamoxifen; 2 P = 0.1).
Our study showed that mean value of T/N ratio tended to decrease in both recurrence and radiation necrosis as tumor size decreased (Table 1).
Moreover, another study by Itoi et al. [1] reported a decrease in recurrence rate of anterior shoulder dislocation at a mean follow-up of 15.5 months in patients with the arm immobilized in external rotation after glenohumeral reduction.
The folic acid groups had a lower relative risk of NTDs in offspring of 0.28 compared to the other groups, indicating a 78% decrease in recurrence risk of NTDs.
At 3 years from switching treatment (approximately 5 years after starting hormonal treatment), AI therapy was associated with an absolute 3.1% (SE = 0.6%) decrease in recurrence (5.0% for AI vs. 8.1% for tamoxifen since switch; 2 P < 0.00001) and an absolute 0.7% (SE = 0.3%) decrease in breast cancer mortality (1.7% for AI vs. 2.4% for tamoxifen since switch; 2 P = 0.02).
‐No decrease in birth weight ‐No decrease in gestational age A decrease in recurrence of NSCL/P in the group of study subjects compared to an historical control group obtained from the populations served by the craniofacial clinics participating in the study.
